Executive Moves | Healthcare | BioTuesdays by Kilmer Lucas IR

Executive Moves

Valion board chair Thomas Jensen brings biotech turnaround experience to advance Entolimod

Valion Bio (NASDAQ: VBIO) has outlined the perspectives of its new board chair, Thomas H. Jensen, on advancing Entolimod—an investigational Toll-like receptor 5 (TLR5) agonist being developed as a potential medical...

October 5, 2026

Executive Moves

Perimeter appoints finance executive Michelle Caron to BOD

Perimeter Medical Imaging AI (TSX-V: PINK; OTCQX: PYNKF) has announced that Michelle Caron, CPA, has been appointed to its board of directors (BOD), effective immediately. In a finance career spanning more than 28...

October 2, 2026

Executive Moves

Lynn Chapman joins AI/ML as CFO

AI/ML Innovations (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) has appointed Lynn Chapman, CPA, CA, as chief financial officer (CFO), effective October 1, 2026. Mr. Chapman brings more than 15 years of financial and managerial...

October 2, 2026

Executive Moves

Robert DiTota joins Nexalin as senior strategic advisor

Nexalin Technology (NASDAQ: NXL) has announced the appointment of Robert DiTota as senior strategic advisor, global commercialization, effective September 15, 2026. Mr. DiTota brings more than 20 years of neuroscience...

September 29, 2026

Executive Moves

Valion appoints life sciences veteran Dean Zikria as interim CEO and announces board leadership transitions

Valion Bio (NASDAQ: VBIO) has announced the appointment of Dean Zikria as interim CEO, along with leadership changes aimed at strengthening alignment and execution as it advances Entolimod and evaluates strategic...

September 24, 2026

Executive Moves

Q32 Bio names Drs. José Trevejo as CMO and Ellie Hershberger as CDO

Q32 Bio (NASDAQ: QTTB) has announced the appointment of José Trevejo, MD, PhD, as chief medical officer (CMO) and Ellie Hershberger, PharmD, as chief development officer (CDO). Prior to joining Q32 Bio, Dr. Trevejo...

September 14, 2026

Executive Moves

Chris Benecchi joins Inventiva as COO

Inventiva (Euronext Paris and NASDAQ: IVA) has announced the appointment of biopharmaceutical leader Chris Benecchi as chief operating officer (COO). Mr. Benecchi brings 30 years of biopharmaceutical leadership across...

September 2, 2026

Executive Moves

Valion announces changes to management and BOD

Valion Bio (NASDAQ: VBIO) has announced that its current chief financial officer, Lisa Wolf, has also been named president and chief operating officer, effective immediately, following the departure of former chief...

September 1, 2026

Executive Moves

Profound strengthens leadership team with appointment of Richard Fabian as president

Profound Medical (NASDAQ: PROF; TSX: PRN) has appointed Richard Fabian as president, effective immediately, succeeding Mathieu Burtnyk, PhD, who has assumed the newly created position of chief technology officer. Mr...

September 1, 2026

Executive Moves

Healthcare investor veteran Greg Ciongoli joins REGENXBIO’s board

REGENXBIO (NASDAQ: RGNX) has announced the appointment of Greg Ciongoli to its board of directors, effective August 25, 2026. Mr. Ciongoli brings extensive experience in biotechnology investing, capital allocation, and...

August 26, 2026

Executive Moves

Alejandro Carrillo joins Stemtech as president, Latin markets

Stemtech Corporation (OTCID: STEK) has announced the appointment of Alejandro Carrillo as president, Latin markets. Mr. Carrillo joined Stemtech as general manager of Stemtech Mexico in 2015, where he built the market...

August 20, 2026

Executive Moves

Defence appoints Dr. Ryan Simms as COO

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Ryan Simms, PhD, as chief operating officer (COO) and head of radiopharmaceutical programs, strengthening the company’s leadership and...

August 17, 2026

Executive Moves

Kamada transitions CFO; launches search for successor

Kamada (NASDAQ: KMDA; TASE: KMDA.TA) has announced that CFO Chaime Orlev will step down effective December 31, 2026, to pursue other opportunities and will provide transitional support to the incoming CFO. The company...

August 12, 2026

Executive Moves

Defence appoints Dr. Amie Phinney as president and CEO

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Dr. Amie Phinney, PhD, MBA, as president and CEO, effective August 1, 2026. Sébastien Plouffe, founder and CEO, will assume the position of executive...

August 6, 2026

Executive Moves

Michelle Gilson joins Rani BOD

Rani Therapeutics Holdings (NASDAQ: RANI) has announced the appointment of Michelle Gilson to its board of directors (BOD). Ms. Gilson will serve as chair of the audit committee. Most recently, Ms. Gilson served as...

August 4, 2026

Executive Moves

Finance leader Dr. Neera Ravindran joins Unnatural Products as CFO

Closely held Unnatural Products (UNP) has announced the appointment of Neera Ravindran, MD, MBA, as chief financial officer (CFO). Dr. Ravindran brings more than 20 years of deep public markets and private company...

July 22, 2026

Executive Moves

Laurie Keating joins Kalaris BOD

Kalaris Therapeutics (NASDAQ: KLRS) has announced the appointment of Laurie Keating to its board of directors (BOD), effective August 1, 2026, and the departure of Morana Jovan-Embiricos from the board. Ms. Keating...

July 7, 2026

Executive Moves

Longeveron appoints Marie Washburn as CFO

Longeveron (NASDAQ: LGVN) has announced the appointment of Marie Washburn as senior vice president and chief financial officer (CFO), effective July 13, 2026. Ms. Washburn has served as Longeveron’s vice president...

July 7, 2026

Executive Moves

Inogen appoints Andy Reding as COO

Inogen (NASDAQ: INGN) has announced the appointment of Andy Reding to the newly created role of chief operating officer (COO), effective Monday, July 6, 2026. Mr. Reding will be responsible for driving revenue and...

July 2, 2026

Executive Moves

Dr. Iain Dukes joins Dogwood as chair of SAB

Dogwood Therapeutics (NASDAQ: DWTX) has announced the appointment of Iain Dukes, PhD, as chair of the company’s scientific advisory board (SAB). Dr. Dukes is a veteran biopharma industry executive and partner with...

June 30, 2026

Executive Moves

Candel appoints Mark Sims as CCO

Candel Therapeutics (NASDAQ: CADL) has announced the appointment of Mark Sims as its chief commercial officer (CCO), effective July 6, 2026. Mr. Sims will lead Candel’s commercial strategy and launch readiness for...

June 25, 2026

Executive Moves

Dr. Jeff Coller joins 4basebio’s SAB

4basebio (AIM: 4BB) has appointed Jeff Coller, PhD, to its strategic advisory board (SAB). Dr. Coller is a globally recognized expert in mRNA biology and translation. According to 4basebio, his understanding of...

June 15, 2026

Subscribe